Radiolabeled compounds which are erlotinib analogs that feature a radioactive halogen and processes of preparing same are disclosed. Uses of these radiolabeled compounds in radioimaging, for identifying and monitoring a level, distribution and/or mutational status of deregulated EGFR, and/or in radiotherapy, are also disclosed.
本发明公开了具有放射性卤素的
厄洛替尼类似物的放射性标记化合物及其制备方法。本发明还公开了这些放射性标记化合物在放射性成像中的用途,用于识别和监测
EGFR失调的
水平、分布和/或突变状态,以及在放射治疗中的用途。